Immuno-informatics Study Identifies Conserved T Cell Epitopes in Non-structural Proteins of Bluetongue Virus Serotypes: Formulation of Computationally Optimized Next-Generation Broad-spectrum Multiepitope Vaccine
Harish Babu KollaiD, Mansi Dutt, Anuj KumariD, Roopa Hebbandi NanjundappaiD, Tobias K. KarakachiD, Karam Pal SinghiD, David J. KelviniD, Peter MertensiD, Channakeshava Sokke UmeshappaiD
Abstract
Bluetongue (BT) is a significant arboviral disease affecting sheep, cattle, goats, and wild ruminants, posing serious economic challenges to livestock industry. Control efforts have been hampered by the existence of over 32 distinct BT virus (BTV) serotypes and the absence of broad-spectrum vaccines. Some key non-structural proteins of BTV, including NS1, NS2, and NS3, exhibit notable amino acid sequence conservation. Our findings reveal that mouse MHC class I (MHC-I) CD8+ T cell epitopes are highly conserved in NS1 and NS3, while MHC-II epitopes are prevalent in all the three non-structural NS 1-3 proteins. Similarly, both class I and II Bovine Leukocyte antigen-restricted CD8+ and CD4+ T cell epitopes are conserved within NS1, NS2, and NS3 proteins. To construct in silico broad-spectrum vaccine, we subsequently screened these conserved epitopes based on antigenicity, allergenicity, toxicity, and solubility. Modeling and Refinement of the 3D structure models of vaccine constructs were achieved using protein modeling web servers. Our analysis revealed promising epitopes that exhibit strong binding affinities with low energies against two TLR receptors (TLR3 and TLR4). To ensure atomic-level stability, we evaluated the docking complexes of epitopes and receptors through all-atom molecular dynamics simulations (MDS). Encouragingly, our 100 nanoseconds MDS showed stable complexes with minimal RMSF values. Our study offers valuable insights into these conserved T cell epitopes as promising candidates for a broad-spectrum BT vaccine. We therefore encourage for their evaluation in animal models and natural hosts to assess their immunogenicity, safety, and efficacy for field use in the livestock.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 16
- FWCI
- 2.17
- Field percentile
- top 11%
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Unleashing the Immune Arsenal: Development of Broad-spectrum Multiepitope Bluetongue Vaccine Targeting Conserved T Cell Epitopes of Structural Proteins
Harish Babu Kolla, Anuj Kumar, … Channakeshava Sokke Umeshappa·BMC GenomicsPeer-reviewed·Apr 17, 2026
- A novel vaccine and drug targets for global eradication of bovine tuberculosis: Holistic frameworks for construction of a potent vaccine and identification of drug targets
Pooja Pawar, Sandhya Samarasinghe, Don Kulasiri·bioRxiv·May 12, 2026
- Design of multi-epitope vaccine candidate against Brucella type IV secretion system (T4SS)
Zhengwei Yin, Min Li, … Fengbo Zhang·PLoS ONEPeer-reviewed·Aug 10, 2023
- Computational design of a multi-epitope vaccine against M. tuberculosis
Abdulrasheed Buhari, Peter Okutu, … Sodiq Ayobami Hameed·bioRxiv·Jul 15, 2026
- In silico design of a multi-epitope vaccine against tick-borne encephalitis virus via immunoinformatic analysis
Bingjie Wang·bioRxiv·Oct 26, 2024
- Exploring B and T-cell epitopes for constructing a Novel Multiepitope vaccine to combat emerging Monkeypox infection: A Reverse Vaccinology approach
Hassan Yousaf, Anam Naz·bioRxiv·Dec 9, 2022